阿帕他胺联合雄激素剥夺治疗使转移性去势敏感性前列腺癌患者前列腺特异性抗原深度、快速且持久下降,与TITAN研究中更长的生存和改善的临床结局相关
本文为TITAN研究的事后探索性分析,评估转移性去势敏感性前列腺癌患者接受阿帕他胺(240 mg/日)或安慰剂联合雄激素剥夺治疗后的PSA动力学及其与结局的关联。阿帕他胺组PSA深度下降比例更高,且3个月时深度PSA下降与更长的OS、rPFS、至PSA进展时间和至去势抵抗时间相关。
要点
- 阿帕他胺组任意时间PSA较基线下降≥50%、≥90%或降至≤0.2 ng/ml的比例分别为90%、73%和68%,安慰剂组分别为55%、29%和32%。
- 治疗3个月时,阿帕他胺组PSA下降≥90%或降至≤0.2 ng/ml的比例分别为59%和51%,安慰剂组分别为13%和18%。
- 3个月时深度PSA下降与更长OS(HR 0.35;95%CI 0.25-0.48)、rPFS(HR 0.44;95%CI 0.30-0.65)、至PSA进展时间(HR 0.31;95%CI 0.22-0.44)和至去势抵抗时间(HR 0.38;95%CI 0.27-0.52)相关(P<0.0001)。
核心结论
- 阿帕他胺联合ADT可诱导稳健(快速、深度且持久)的PSA下降,且该下降与包括长期生存在内的临床结局改善相关。
研究设计与样本
- TITAN研究的事后探索性分析,该研究为III期、随机、双盲、安慰剂对照、跨国研究。
- 患者按1:1接受阿帕他胺(240 mg/日)或安慰剂联合持续ADT。
- 采用标志点分析、Kaplan-Meier法和Cox比例风险模型评估PSA动力学与结局的关联。
- rPFS分析随访22.7个月,OS、至PSA进展时间和至去势抵抗时间分析随访44.0个月。
主要发现
- 研究期间任意时间最佳确认PSA较基线下降≥50%、≥90%或降至≤0.2 ng/ml的比例:阿帕他胺组分别为90%、73%和68%,安慰剂组分别为55%、29%和32%。
- 阿帕他胺治疗3个月时,最佳深度PSA下降≥90%或降至≤0.2 ng/ml的比例:阿帕他胺组分别为59%和51%,安慰剂组分别为13%和18%。
- 3个月标志点时达到深度PSA下降(相较无下降)与更长OS相关(HR 0.35;95%CI 0.25-0.48)。
- 3个月标志点时达到深度PSA下降(相较无下降)与更长rPFS相关(HR 0.44;95%CI 0.30-0.65)。
- 3个月标志点时达到深度PSA下降(相较无下降)与更长至PSA进展时间(HR 0.31;95%CI 0.22-0.44)和至去势抵抗时间(HR 0.38;95%CI 0.27-0.52)相关,所有P<0.0001;6个月和12个月标志点观察到相似结果。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The first interim analysis of the phase III, randomized, double-blind, placebo-controlled, multinational TITAN study demonstrated improved overall survival (OS) and radiographic progression-free survival (rPFS) with apalutamide added to ongoing androgen deprivation therapy (ADT) in patients with metastatic castration-sensitive prostate cancer. The final analysis confirmed improvement in OS and other long-term outcomes. We evaluated prostate-specific antigen (PSA) kinetics and the association between PSA decline and outcomes in patients with metastatic castration-sensitive prostate cancer from TITAN. PATIENTS AND METHODS: Patients received apalutamide (240 mg/day) or placebo plus ADT (1 : 1). This post hoc exploratory analysis evaluated PSA kinetics and decline in relation to rPFS (22.7 months' follow-up) and OS, time to PSA progression, and time to castration resistance (44.0 months' follow-up) in patients with or without confirmed PSA decline using a landmark analysis, the Kaplan-Meier method, and Cox proportional hazards model. RESULTS: One thousand and fifty-two patients (apalutamide, 525; placebo, 527) were enrolled. Best confirmed PSA declines (≥50% or ≥90% from baseline or to ≤0.2 ng/ml) were achieved at any time during the study in 90%, 73%, and 68% of apalutamide-treated versus 55%, 29%, and 32% of placebo-treated patients, respectively. By 3 months of apalutamide treatment, best deep PSA decline of ≥90% or to ≤0.2 ng/ml occurred in 59% and 51% of apalutamide- and in 13% and 18% of placebo-treated patients, respectively. Achievement of deep PSA decline at landmark 3 months of apalutamide treatment was associated with longer OS [hazard ratio (HR) 0.35; 95% confidence interval (CI) 0.25-0.48), rPFS (HR 0.44; 95% CI 0.30-0.65), time to PSA progression (HR 0.31; 95% CI 0.22-0.44), and time to castration resistance (HR 0.38; 95% CI 0.27-0.52) compared with no decline (P < 0.0001 for all). Similar results were observed at landmark 6 and 12 months of apalutamide treatment. CONCLUSIONS: Apalutamide plus ADT demonstrated a robust (rapid, deep, and durable) PSA decline that was associated with improved clinical outcomes, including long-term survival.
引用
- Chowdhury S, Bjartell A, Agarwal N, et al. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. Ann Oncol. 2023. PMID: 36858151. doi:10.1016/j.annonc.2023.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。